Provenge Immunotherapy

"Why The New Dendreon Analysis Does Matter — And Why It Doesn’t"

"Last night, a researcher from Duke University presented an analysis that may help cement the case that Dendreon’s Provenge extends the lives of men with metastatic prostate cancer – if, that is, you think additional proof is needed."

Read more here